Search research articles
Contact Us
Filters
Showing results (381-390 of 419) with videos related to
Page
of 42
Sort By:
The New England Journal of Medicine
|
September 16, 2024
Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D Wolchok, Vanna Chiarion-Sileni, Piotr Rutkowski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 18, 2020
Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial
Alexander M M Eggermont, Christian U Blank, Mario Mandala, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 15, 2019
Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma
Alexander M M Eggermont, Christian U Blank, Mario Mandala, et al.
The New England Journal of Medicine
|
September 30, 2014
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma
Georgina V Long, Daniil Stroyakovskiy, Helen Gogas, et al.
The New England Journal of Medicine
|
September 12, 2017
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
Jeffrey Weber, Mario Mandala, Michele Del Vecchio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 25, 2021
Reply to E. Hindié
Alexander M M Eggermont, Christian U Blank, Mario Mandala, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 27, 2022
Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma
Oliver J Kennedy, Michal Kicinski, Sara Valpione, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 14, 2023
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238
James Larkin, Michele Del Vecchio, Mario Mandalá, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 5, 2023
Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma
Oliver John Kennedy, Michal Kicinski, Sara Valpione, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 10, 2022
Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma
Inês Pires da Silva, Tasnia Ahmed, Jennifer L McQuade, et al.
Page
of 42
Search research articles
Search
Showing results (381-390 of 419) with videos related to
Sort By:
Page
of 42
The New England Journal of Medicine
|
September 16, 2024
Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D Wolchok, Vanna Chiarion-Sileni, Piotr Rutkowski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 18, 2020
Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial
Alexander M M Eggermont, Christian U Blank, Mario Mandala, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 15, 2019
Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma
Alexander M M Eggermont, Christian U Blank, Mario Mandala, et al.
The New England Journal of Medicine
|
September 30, 2014
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma
Georgina V Long, Daniil Stroyakovskiy, Helen Gogas, et al.
The New England Journal of Medicine
|
September 12, 2017
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
Jeffrey Weber, Mario Mandala, Michele Del Vecchio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 25, 2021
Reply to E. Hindié
Alexander M M Eggermont, Christian U Blank, Mario Mandala, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 27, 2022
Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma
Oliver J Kennedy, Michal Kicinski, Sara Valpione, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 14, 2023
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238
James Larkin, Michele Del Vecchio, Mario Mandalá, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 5, 2023
Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma
Oliver John Kennedy, Michal Kicinski, Sara Valpione, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 10, 2022
Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma
Inês Pires da Silva, Tasnia Ahmed, Jennifer L McQuade, et al.
Page
of 42